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Major Potential Confounder 
Not Addressed
Jennifer Vines
This is the ﬁ  rst of 12 Correspondence pieces in this issue that are in response 
to an important PLoS Medicine Research Article: Auvert B, Taljaard D, 
Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. (2005) Randomized, 
controlled intervention trial of male circumcision for reduction of HIV 
infection risk: The ANRS 1265 trial. PLoS Med 2(11): e298. Readers 
wishing to add their own views may do so using our E-letters facility, where 
the debate continues.
In the article by Auvert et al. regarding incidence rates of 
HIV infection in circumcised versus uncircumcised men, the 
ﬁ  nding of 60% fewer infections among the former group 
is compelling [1]. I must echo the comments submitted 
by others and question these ﬁ  ndings in light of the fact 
that the authors did not control for other sources of HIV 
transmission, such as exposure through blood transfusions 
or infected needles. While the literature supports sexual 
(primarily heterosexual) activity as the main route of 
HIV transmission in South Africa, the behavioral factor 
of “attending a clinic for a health problem related to the 
genitals,” initially reported by approximately 10% of both 
the intervention and the control group, corresponds to 
a signiﬁ  cantly elevated HIV incidence rate. It is plausible 
that these men presented with urogenital complaints that 
resulted in antibiotic or other therapeutic treatments 
administered with unsterile needles. This could represent 
a signiﬁ  cant confounder since the uncircumcised men, 
if indeed more prone to sexually transmitted infections 
(STI), were more likely to present for STI care and become 
infected through the health-care setting rather than through 
unprotected sexual intercourse. Controlling for this route 
of infection could result in a smaller difference between 
HIV infection rates in the circumcised versus uncircumcised 
groups, indicating that circumcision may not be as effective 
at decreasing HIV transmission as the article suggests.  
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The Protective Effect of Male 
Circumcision as a Faith Lift for 
the Troubled Paradigm of HIV 
Epidemiology in Sub-Saharan Africa 
John J. Potterat, Devon D. Brewer, Stephen Q. Muth, 
Stuart Brody
Auvert and colleagues present preliminary evidence for the 
protective effect of male circumcision on HIV acquisition [1]. 
Their report also reveals several problems with the widely 
held assumption that penile–vaginal sex accounts for the 
overwhelming majority of HIV transmission in sub-Saharan 
Africa. 
We are bafﬂ  ed that the factor most strongly associated with 
incident HIV infection—attendance at “a clinic for a health 
problem related to the genitals” (rate ratio, 5.7)—is neither 
highlighted nor speciﬁ  cally discussed. Given evidence for 
increased risk of acquiring HIV from treatment for sexually 
transmitted diseases (STDs) in sub-Saharan Africa (relative 
to untreated STDs) [2], such a context for HIV acquisition 
should have been more assiduously explored, especially 
regarding nosocomial transmission. 
Regrettably, the authors did not control for blood 
exposures (e.g., other types of medical or dental care, 
including care from “street doctors” and village injectionists, 
injections with syringes kept at home, ritualistic procedures, 
and injection drug use). Nor did they assess anal intercourse, 
the variable most strongly associated with sexual transmission 
of HIV. Anal intercourse is not uncommon in sub-Saharan 
Africa [3]. The authors also did not ask participants to specify 
the sex of their nonspousal partners, despite much evidence 
for bisexual behavior on the part of many “heterosexual” men 
in sub-Saharan Africa [3]. 
Furthermore, the authors did not report the relationship 
between level of condom use and HIV incidence. The 
need for more detailed investigation of sexual exposures 
is underlined by the negligible associations between such 
traditional measures of sexual risk—any type of unprotected 
sex, the number of sexual exposures (“contacts”), and the 
number of nonspousal partners—and HIV incidence [1]. 
Indeed, these results replicate the frequent lack of association 
between sexual behavior variables and HIV incidence or 
epidemic trajectories in sub-Saharan Africa [4]. (The authors 
should also report HIV incidence in persons reporting no 
sexual activity during speciﬁ  ed study intervals.) Of concern 
as well is the high per coital act–HIV transmission probability 
implied by the data presented. A high transmission 
probability would suggest that the HIV prevalence in their 
participants should be greater than the 4%–5% observed at 
baseline.
Until all modes of HIV transmission—by sex and by 
puncturing—are comprehensively investigated [5,6], the 
most effective means of preventing HIV transmission will 
remain shrouded. In light of the anomalies and lacunae in 
Auvert and colleagues’ study, the protective effect of male 
circumcision they observed amounts to a faith lift for the 
empirically beleaguered paradigm of heterosexual HIV 
transmission in sub-Saharan Africa [7].  
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Estimated Protection Too Conservative
James D. Shelton
The randomized study by Auvert et al. [1] on male 
circumcision to prevent HIV infection is clearly a landmark 
study, which supports compelling observational evidence 
of strong protection [2]. However, I believe the highlighted 
60% degree of protection from the “intent-to-treat” analysis 
is probably too conservative. Deep in the article, we learn 
that the “per protocol” analysis, which addressed the 
10.3% of men allocated to the noncircumcision group 
who nevertheless decided to be circumcised outside of the 
study, found a relative risk of 0.24%—or a protective effect 
of 76%. 
Some might argue that the intent-to-treat analysis is 
more scientiﬁ  c, and reduces the impact of some selection 
or behavioral bias in those who opted for circumcision 
notwithstanding their allocation to the control arm. 
For example, it could be that men allocated to the 
noncircumcision group who were predisposed to less risky 
behavior but wanted to be extra safe might have chosen to 
be circumcised. In the opposite direction, those who were 
indulging most in risky behavior might have chosen to be 
circumcised to reduce their risk.
In my view, however, if we are interested in the true 
biologic effect, it is not very scientiﬁ  c to bias in favor of the 
analysis with a 10% contamination of that biological effect. 
In this study, we are fortunate enough to have quite richly 
reported behavioral data. More analysis of the per protocol 
analysis should have been presented, including the behavior 
of the crossovers. It is reasonably likely that any difference in 
the behavior of the crossovers would have little impact since, 
in the intent-to-treat analysis, adjustment for the increase in 
riskier behavior in the treatment group had little effect on 
the overall result.
The paper should have had prominent presentation 
of both analyses. In either case, the protection is quite 
substantial. But from an epidemiologic and personal 
perspective, what amounts to a failure rate of 40% versus 24% 
could be quite important.  
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On Evidence in Support of Male 
Circumcision in HIV Prevention: 
What Next?
Adamson Sinjani Muula
The study by Auvert et al. [1] will certainly go into the history 
of HIV prevention as a landmark. The study is important 
because the results are the ﬁ  rst blinded randomized 
study demonstrating that HIV can be prevented by male 
circumcision (MC). Double-blinded studies are considered 
to be the gold standard in research but because of the nature 
of this intervention, double blinding was impossible—i.e., it 
was impossible for the men to be circumcised without them 
knowing that they had been circumcised. 
The study suggests that MC could join the interventions for 
HIV/AIDS already available—i.e., highly active antiretroviral 
therapy (HAART), short-course antiretroviral therapies and 
caesarean section in preventing mother-to-child transmission, 
postexposure prophylaxis, condoms, abstinence, and 
treatment of sexually transmitted infections (STIs). Like 
many other health interventions, MC (if its effectiveness is 
further demonstrated in subsequent randomized studies and 
then adopted within national policies) will be indicated and 
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suitable for some people, but not for others, for a variety of 
reasons. It would therefore be unfortunate if we were to start 
promoting MC at the expense of other intervention measures. 
The authors did not suggest that we should do so, but there is 
always the danger that some people will seek to boost efforts 
on one intervention whilst neglecting others.
The other challenge is that medical practice is 
conservative—i.e., it is unlikely that any country will 
immediately include MC in its policy for the prevention 
of HIV. The reasons include the following: these ﬁ  ndings 
may not be corroborated in forthcoming studies and the 
potential harms still need to be considered in order to assess 
the cost–beneﬁ  t ratio. Even in South Africa where the study 
was carried out, it will be a while before MC is incorporated 
into the national HIV prevention policy. Interestingly, 
however, the institutional review board stopped the study 
prematurely—as is always deemed ethical—suggesting 
implicitly perhaps their endorsement of MC and that it ought 
to be standard practice. 
The authors indicate that “to wish to be circumcised” 
was one of the inclusion criteria. It is not clear to me what 
“wishing” meant—i.e., was it that they found MC acceptable 
or that they wanted to be circumcised but, for some reason, 
had not had the opportunity? If the interpretation is the 
latter, it would be important later to identify the barriers 
to MC that may operate in countries in southern Africa. 
Knowledge of these barriers will inform the policy debates. 
While the policy debates rage, the scientiﬁ  c community 
has an enormous responsibility—i.e., ensuring that well-
conducted studies are carried out in other settings to either 
conﬁ  rm or dispute the ﬁ  ndings. Results from other settings 
will be awaited with eagerness. 
Researchers in the HIV ﬁ  eld face the dilemma of not 
subjecting their study subjects to undue harm through 
stigmatization and discrimination. In several southern African 
countries, providing HIV test results to clients of health 
services and research participants is at the discretion of the 
client. The fact that there is no requirement for people 
who test positive to inform others who may beneﬁ  t from the 
disclosure is, in my opinion, an important omission in the 
prevention of HIV in the region. It may be useful to include, 
at the time of obtaining informed consent, the statement, 
“Should you test HIV positive, we will encourage you to 
inform your sexual partners about the test results.” 
While it has been demonstrated that MC can be effective, 
it has yet to be determined why this might be the case. The 
authors have suggested that perhaps the keratinization that 
may ensue, more rapid drying of the glans penis after sexual 
intercourse, and prevention of STIs may be reasons. These 
are plausible explanations, but it will require separate studies 
to elucidate the mechanism(s). 
The authors suggest that if women were aware of the 
effectiveness of MC, this would in turn lead them to 
encourage males to be circumcised. While I agree that all 
stakeholders ought to be mobilized in promoting an effective 
HIV intervention, or any public health intervention, the 
“role” of women, sadly, is minimal in decision making in most 
parts of the southern African region. But this does not mean 
that attempts should not be made to involve women.  
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Two Groups Not on All Fours
Hugh Young
A prime requirement in any controlled study is that as far 
as possible, all conditions apart from the one being tested 
should be the same.
In the Auvert study, the men from the intervention 
group were instructed, in effect, as follows: “When you are 
circumcised you will be asked to have no sexual contact in the 
six weeks after surgery. To have sexual contact before the skin 
of your penis is completely healed could lead to infection if 
your partner is infected with a sexually transmitted disease. 
It could also be painful and lead to bleeding. If you desire 
to have sexual contact in the six weeks after surgery, despite 
our recommendation, it is absolutely essential that you use a 
condom” (Text S3 in [1]).
So the men in the intervention group were given very 
different instructions about sexual behaviour than those 
in the control group—in precisely the ﬁ  eld where their 
risk of HIV infection was most affected. This could have 
differentially affected their sexual behaviour, and perhaps 
how they reported it. The time they spent waiting for and 
recovering from their surgery could also have exposed them 
to more safe-sex information and inﬂ  uence than the control 
group.
The control group was given no medical intervention at all. 
The study would have come closer to reaching equivalence 
between the two groups if a placebo surgery had been 
performed on the penis, such as opening and suturing an 
annular incision on the shaft, but leaving the foreskin, the 
supposed portal of HIV infection. The control group would 
then have needed identical instructions to those given to the 
intervention group; then, the two groups would have had 
much more equivalent risk.  
Hugh Young
Circumstitions.com
E-mail: hugh@buzz.net.nz
References
1.  Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, et al. 
(2005) Randomized, controlled intervention trial of male circumcision for 
reduction of HIV infection risk: The ANRS 1265 trial. PLoS Med 2: e298. 
DOI: 10.1371/journal.pmed.0020298
Citation: Young H (2006) Two groups not on all fours. PLoS Med 3(1): e75.
Copyright: © 2006 Hugh Young. This is an open-access article distributed under 
the terms of the Creative Commons Attribution License, which permits unrestricted 
January 2006  |  Volume 3  |  Issue 1  |  e66  |  e75PLoS Medicine  |  www.plosmedicine.org 0139
use, distribution, and reproduction in any medium, provided the original author and 
source are credited.
Competing Interests: The author has declared that no competing interests exist.
DOI: 10.1371/journal.pmed.0030075
Rubbery Figures?
Michael Glass 
I have been following reports of the Auvert et al. study [1] 
and have found four different ﬁ  gures for seroconversions.
An abstract from the 3rd International AIDS 
Conference (Rio de Janeiro, 24–27 July 2005) reported 
15 seroconversions in the circumcised group and 45 
seroconversions in the uncircumcised group [2]. On 29 
July 2005, the Science and Development Network reported 
18 seroconversions in the circumcised group and 51 in 
the uncircumcised group [3]. A paper in the New Scientist, 
published on 6 August 2005, reported 15 seroconversions 
in the circumcised group but 51 in the uncircumcised 
group [4]. Finally, on 23 October 2005, a paper in PLoS 
Medicine reported that there were 20 seroconversions in 
the circumcised group and 49 in the uncircumcised group 
[1]. It seems strange that the ﬁ  gures should have so much 
variance.
If we just look at the ofﬁ  cial ﬁ  gures—15 to 45 at the 
International AIDS Conference and 20 to 49 in PLoS 
Medicine—between 1 August 2005 and 23 October 2005, it 
appears that there have been four seroconversions among 
the uncircumcised and ﬁ  ve seroconversions among the 
circumcised. In less than three months, a 3:1 difference has 
shrunk to a 2.45:1 difference.
Why are the numbers of seroconversions so much at 
variance in reports published by reputable journals?  
Michael Glass
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Rush to Judgment
Richard Winkel
How have Auvert et al. [1] controlled for the 
nonrandomization implicit in using a pool of men who want 
to be circumcised? Such self-selection increases the likelihood 
of recruiting men who are experiencing sexual difﬁ  culties—
such as tight foreskins, a common but easily treatable 
problem leading to foreskin tearing—which would certainly 
skew the statistics.
I also ﬁ  nd it fascinating that the male prepuce has gone 
straight from being an inconsequential “ﬂ  ap of skin” to being 
a complex immunological organ, just in time to be infected 
by a virus that targets immune cells. Is this an indication 
of accelerated evolution, perhaps driven by medicine’s 
century-long obsession with the purported pathologies of 
male genitals, or perhaps just a demonstration of medicine’s 
capacity to deceive the public?
It’s equally fascinating that the obvious concern about 
the impact of male circumcision on male-to-female HIV 
transmission seems to be of no interest to researchers. There 
are good reasons to expect [2,3]—and empirical evidence 
for (see “Heterosexual Transmission, Europe versus the 
United States” at http:⁄⁄www.circumstitions.com/HIV.
html#hetero)—the thesis that male genital mutilation 
causes a signiﬁ  cant increase in the rate of male-to-female 
HIV transmission. The net effect of circumcision in a given 
population may be evident in the vastly different rates of HIV 
infection in the United States and Europe, where routine 
medical genital surgery on normal, healthy, nonconsenting 
children is unknown. Although the collateral damage of male 
circumcision to women might be prevented by routine female 
genital mutilation, as shown in this impolitic study [4], one 
would hope common sense and decency might preemptively 
stop a new medical crusade against normal human anatomy.  
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Male Circumcision Increases Risk 
for Females
Jonathan Sykes 
Auvert et al. argue that male circumcision provides a protective 
effect for males [1]. On the other hand, Chao et al. identiﬁ  ed 
circumcision of the male partner as a risk factor for females 
[2]. Auvert et al. do not provide information on the overall 
effect of male circumcision on HIV transmission and infection 
[1]. Male circumcision may in fact worsen the epidemic. It 
is imperative, therefore, that further studies be conducted 
to determine the overall effect before implementing mass 
circumcision campaigns to control HIV infection.  
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The Money Issue
Mpho Selemogo
Auvert et al. must be commended for showing some 
appreciation of the ethical issues raised by their research trial 
[1]. The Research Article itself and the accompanying ethical 
review by Cleaton-Jones [2], however, curiously seem to take 
the money issue lightly. The PLoS Medicine Editorial is quite 
right in identifying the R300 payment to participants as an 
issue [3].
Rather than just identifying what R300 means in terms of 
the euro, we need an idea of the sum’s effect on the average 
person enrolled in the study in order to best review issues of 
autonomy, which are often so problematic in such research. 
What was its impact on the recruitment process? Was the 
average income for the participants so low that declining to 
participate in the study and turning down the money was not 
an economically feasible option? The absence of such critical 
socioeconomic data leaves us wondering if this money was 
meant as a force for recruitment or indeed as a compensation 
for participation, as the authors assert.  
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Male Circumcision and HIV in Africa 
Taiwo Lawoyin, O. A. Kehinde 
We wish to congratulate Auvert et al. [1] on their work and 
wish them more success in their endeavors. Quite a number 
of studies have shown that circumcised males in heterosexual 
unions do have lower HIV rates [2–4]. It would be good to 
know to what extent circumcision affects the HIV rates in sub-
Saharan African countries presently bearing the brunt of the 
disease.
Though ecological studies should be interpreted with 
caution, it would also be interesting to ﬁ  nd out how this 
information helps us to better understand why some African 
countries with similar behavior have a much lower HIV rate 
than others [4–6]. West African countries, for example, have 
signiﬁ  cantly higher circumcision rates than countries in the 
eastern and southern parts of Africa. HIV rates also appear to 
be generally lower in West Africa [7].
Also it would be interesting to ﬁ  nd out if more African 
males who are not circumcised are ready to have this 
procedure done as a form of added protection, as there seem 
to be pockets of resistance to the procedure [8,9].  
Taiwo Lawoyin (tlawoyin@skannet.com)
O. A. Kehinde 
University College Hospital Ibadan
Ibadan, Nigeria
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Authors’ Reply
Jennifer Vines raises the question of other potential sources 
of HIV [1]. During our follow-up, 569 participants received 
blood transfusions, were hospitalized, or received injections. 
We observed 15 infections among those who had such a 
nosocomial risk factor during the period when HIV infection 
occurred. We observed 50 infections among those without 
such a risk factor. In a multivariate analysis of risk factors 
of HIV infection during the follow-up, the presence of a 
nosocomial risk factor was not signiﬁ  cantly associated with 
HIV infection (rate ratio [RR] = 1.7; p = 0.092). Among 
those with a nosocomial risk factor, the protective effect of 
the intervention (intention-to-treat analysis) is about 58%. 
Among those without a nosocomial risk factor, the protective 
effect of the intervention is about 62%. In a multivariate 
analysis, when taking into account the nosocomial risk factors, 
the association between group of randomization and HIV 
infection was unchanged (protection of 60% versus 60%). 
The fact that patients with a nosocomial risk factor were not 
signiﬁ  cantly more at risk of HIV infection, and were protected 
by male circumcision in a similar way to those without a 
nosocomial risk factor, strongly supports the view that the 
majority of HIV infections observed in our study were due to 
sexual transmission.
John Potterat and colleagues make a number of points to 
which we must respond [2]. The association between clinic 
attendance for a health problem related to genitals and 
HIV infection is most likely due to genital herpes, which is 
common in South Africa and strongly associated with HIV. 
We believe that those who became HIV positive also became 
infected with HSV-2 just before, at the same time, or just 
after the acute primary HIV infection. Primary genital herpes 
infection concomitant with HIV infection can lead to clinic 
attendance because of herpes genital lesions, and can explain 
the observed association.
In this population of young men, as shown in Table 4 of 
our Research Article [3], we did not observe any signiﬁ  cant 
association between reported sexual behaviour characteristics 
and HIV infection when controlling for other factors, 
including the randomisation group. However, in univariate 
analysis, there is an association between HIV infection and 
number of sexual contacts (RR = 2.0; p = 0.035) and risk of 
infection (RR = 1.7; p = 0.045). This last variable includes lack 
of condom use. We believe that because of the small number 
of infections, and the importance of male circumcision on 
the transmission of HIV, the factors associated with sexual 
behaviour do not appear in the multivariate analysis. In 
addition, we think that the HIV status of female partners of 
these young men is a key factor. In Table 4, it is clear that HIV 
infection increases with the age of the participants, which is 
a proxy for the risk of having a partner who is infected with 
HIV for two reasons: (1) because the age of female partners 
increase with age of their male partners and (2) because, in 
young women, HIV status is strongly associated with age. 
We did ask the sex of all reported sexual partners. We 
found that 0.07% of these reported partners were men. Three 
participants reported sexual partnerships with men. None 
became infected during the follow-up.
At recruitment, HIV prevalence was 0.7% (two out of 278) 
among those who reported never having any sexual contact, 
and 4.8% (144 out of 2,994) among those who reported 
having sexual contact (p < 0.001).
HIV incidence was about two out of 100 per year in the 
control group during the follow-up. Knowing that HIV 
incidence increases with age, and assuming that the incidence 
is negligible before 17, we can estimate the HIV incidence 
between the age of 17 (median age of ﬁ  rst sexual experience) 
and the age of 21 (age at recruitment) by about half the 
incidence of the control group during the follow-up, leading 
to an estimated HIV incidence of one out of 100 per year. It 
means that the HIV prevalence of the participants between 
this four-year period (17–21) goes up from 0% to 4%. We 
observed about 4.5% at recruitment, which is consistent with 
this analysis.
We agree with the comment by James Shelton [4]. When 
looking at the crossovers, we found that they were protected 
by male circumcision. This implies that the difference 
between the intention-to-treat analysis and the per-protocol 
analysis is at least partly caused by the dilution effect of 
crossovers. Therefore, we believe, as does Shelton, that the 
60% degree of protection obtained from the intent-to-treat 
analysis is probably too conservative.
We also agree with the points made by Adamson S. Muula 
and would like to note that, for many researchers, the results 
of this trial are not surprising and are consistent with many 
other studies published since 1986 [5]. 
With reference to the comment by Hugh Young [6], we 
reported analyses in our paper to account for this six-week 
period and for differences of behaviour between the two 
arms of the trial. These analyses show that the six-week period 
of abstinence cannot explain the outcome of the trial, and 
that participants in the intervention group were slightly 
more sexually active. Therefore, we strongly believe that 
the difference in rate of infection can be attributed to male 
circumcision. We think the study design suggested by Young 
would be unlikely to obtain ethical approval and would be 
unacceptable to participants.
Michael Glass has read a number of reports of our study. 
During the trial, we collected about 12,000 blood samples, 
performed about 12,000 clinical examinations, and collected 
about 48,000 questionnaires. We were careful to enter all 
these data with a double-entry procedure and even a triple-
entry procedure for the laboratory data. This, of course, 
took considerable time. Nevertheless, we wanted to make 
available to the international community some preliminary 
information as soon as possible. We decided to release the 
results of the trial in a preliminary form at the International 
AIDS Society Conference in Rio de Janeiro. It is often 
the case that the results presented in a conference do not 
correspond exactly with those presented in the abstract, and 
that the ﬁ  nal published results can be slightly different from 
those given in the oral presentation. We knew that this might 
be a problem, and we were careful to indicate to the PLoS 
January 2006  |  Volume 3  |  Issue 1  |  e74  |  e67PLoS Medicine  |  www.plosmedicine.org 0142
Medicine editors that the results would be ﬁ  nalized only after 
the conference.
In addition, there is not just one numerical value but two: 
the result given by the per-protocol analysis and the result 
given by the intention-to-treat analysis, each having a wide 
conﬁ  dence interval. 
The magnitude of the effect in a trial of this nature 
cannot, in any case, predict precisely what to expect in an 
actual intervention program for four reasons. Firstly, the 
trial was conducted in a speciﬁ  c population (young men of 
the age range 18–24); it was not representative of the whole 
population. Secondly, the participants received intense 
counselling periodically throughout the follow-up period. 
Thirdly, they were informed that the result of the trial 
was unpredictable. Finally, the duration of the follow-up 
period was short. This is why operational research should be 
conducted to test if male circumcision, in association with 
existing and validated prevention methods, can be used in a 
community intervention. 
Richard Winkel has also raised a number of concerns 
[7]. Our participants were recruited among the general 
population of the area. This neither implies that they are 
representative of this population nor that they are very 
different. HIV prevalence among those who were recruited 
is similar to what was expected, and clinical examination 
rarely revealed a tight foreskin. We do agree that the results 
obtained in this trial have to be conﬁ  rmed by other trials, 
but also, as mentioned above, by conducting operational 
research. 
Winkel seems to believe that the foreskin has only recently 
been linked to the transmission of infectious diseases. 
Hutchinson in 1854 noticed an association between male 
circumcision and a lower rate of syphilis. The ﬁ  rst paper 
on the association between male circumcision and HIV 
infection was published in 1986. In addition, it is possible 
that male circumcision was practiced by the Egyptians, for 
health reasons, at least 3,000 years ago. Contrary to what 
Winkel has written, researchers are working on the effect of 
male circumcision on male-to-female transmission, despite 
technical difﬁ  culties. The ongoing trial in Uganda should 
yield new knowledge on this issue.
The aim is not to conduct a “new medical crusade against 
normal human anatomy” [7]. It is to reduce the mortality 
due to AIDS by reducing the spread of HIV, especially in the 
worst-infected countries.
In response to Jonathan Sykes [8], we would like to point 
out that several well-conducted meta-analyses and systematic 
reviews have shown that male circumcision is associated with 
lower rates of HIV infection among males. These studies 
have been quoted in our paper reporting our trial. It is rarely 
argued that male circumcision might worsen the epidemic, 
even if the safety of male circumcision is a real problem. The 
main remaining scientiﬁ  c problems are (1) to have the result 
of the South African study conﬁ  rmed by the other ongoing 
trials and (2) to demonstrate that safe male circumcision is 
protective at population level by conducting applied research 
studies.
We can assure Mpho Selemogo [9] that we did consider 
the issue he raises very seriously when designing the trial. 
The guidelines of the HREC (the ethics committee of 
the University of the Witwatersrand) are quite clear that 
participation should be voluntary and that there should be 
no evidence of inducement. The minimum basic salary in 
South Africa is roughly R1,500 per month, which translates 
to about R70 per day. The R300 that we gave participants was 
distributed in increments across ﬁ  ve visits. For the inclusion 
visit, participants received R30. For the three-month visit, they 
received R40; for the 12-month visit, R80; and for the ﬁ  nal 
visit, R150. On average, participants received R75 per visit. 
The primary reasoning for an incremental compensation 
was because of the duration of the trial, and also to balance 
requirements of cohort retention. However, the increments 
were within the ethical bounds set by the HREC. In addition, 
we thought that it would eliminate the risk of recruiting 
people wishing to participate for immediate ﬁ  nancial gain. 
We asked all participants why they wanted to be part of 
the study. A very small percentage (0.3%) indicated that 
they were participating for ﬁ  nancial reward. The majority 
participated for the safe and free circumcision and to 
improve their health, 37.7% and 40%, respectively.
The honoraria paid during this trial compare very 
favourably to those paid to participants in other trials in 
the region. (For a drug trial, the current compensation, as 
stipulated by the Medicines Control Council, is R150 per 
visit.)
Finally, we do agree with Taiwo Lawoyin [10]. More 
research is needed to ﬁ  ll the gaps in this area. Nevertheless, 
we hope that these gaps will not be used as arguments to 
delay the use of male circumcision in slowing the spread of 
HIV in those countries of sub-Saharan Africa that have high 
rates of HIV infection and low rates of male circumcision, and 
where acceptability studies have already revealed a potential 
for this prevention method. Male circumcision should always 
be used in combination with other validated prevention 
methods.  
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Male Circumcision and HIV Control 
in Africa 
Michel Garenne
In a recent article, Auvert and colleagues present the results 
of their randomized controlled trial on male circumcision 
to prevent HIV transmission [1]. They conclude that male 
circumcision reduced the risk of HIV infection by some 60% 
(95% conﬁ  dence interval, 32%–76%). The trial was certainly 
well conducted, and it nicely conﬁ  rmed observational studies, 
which came to the same conclusion [2]. However, a number 
of their concluding statements deserve a comment.
Auvert and colleagues claim a “degree of protection 
equivalent to a vaccine of high efﬁ  cacy” [1]. This is obviously 
overstated. A vaccine of high efﬁ  cacy is expected to offer 
long-term protection of 95% or above. Smallpox was 
eradicated with such a highly efﬁ  cient vaccine. If control of 
tetanus, measles, and poliomyelitis has been largely achieved 
in the world, it has been a result of high-efﬁ  cacy vaccines. 
Furthermore, the analogy with vaccines appears misleading. A 
96%-efﬁ  cient measles vaccine means that 96% of vaccinated 
persons exposed to measles are indeed protected against 
infection. Protection lasts for many years, and revaccination 
permits dealing with loss of immunity over time. What Auvert 
and colleagues show is different: they show a 60% reduction 
in disease incidence over an 18-month period among 
circumcised men compared with uncircumcised men with 
similar exposure. To our knowledge, this does not mean that 
those men are really “protected” against HIV, especially in the 
case of repeated exposure. It simply means “reduced risk,” or 
reduced probability of contamination.
A closer analogy of the “reduced risk” offered by male 
circumcision is that offered by contraception. Modern and 
efﬁ  cacious methods such as hormonal contraceptives (pill, 
injectables, implants) or intra-uterine devices (IUDs) do 
offer high protection, usually 99% or above for women who 
are exposed repeatedly (every month) to risk of pregnancy. 
Highly efﬁ  cacious methods do protect these women against 
unwanted pregnancy. On the contrary, a less efﬁ  cacious 
method such as rhythm method (periodic abstinence) 
reduces fecundity by some 50%, but offers little protection 
against unwanted pregnancy. Even though women using 
consistent rhythm methods will have a lower number of 
pregnancies over their lifetime than women who use no 
contraceptive methods at all, they will be unlikely to achieve 
their desired family size, as could women using highly 
effective methods.
Similarly, for persons who are highly exposed to risk of 
HIV infection, as are the young men of South Africa, a 
60% reduction in annual risk will ultimately protect only 
a smaller proportion. Basic probability calculations show 
that in discordant couples exposed for 30 years, some 74% 
will contract the HIV virus if circumcised, compared with 
97% if uncircumcised (with incidence of 11% per year)—a 
small reduction indeed if compared with a highly efﬁ  cacious 
vaccine (comparable ﬁ  gures would be 4% versus 97% for 
children vaccinated against measles who are exposed between 
1 and 15 years of age).
One could argue that the population effect could exceed 
the individual risk for a variety of reasons ranging from 
herd immunity to prevention of other sexually transmitted 
diseases (STIs). If all men are circumcised, then prevalence 
among women will be lower, and men will have lower risk 
of being exposed and infected. However, several natural 
experiments do not conﬁ  rm this argument. For instance, 
Tanzania has some 110 ethnic groups, some groups using 
universal male circumcision, others not circumcising. After 
controlling for urbanization, there was no difference in 
male HIV prevalence between the two groups: in urban 
areas, HIV seroprevalence was 9.5% in circumcised groups 
and 9.7% in uncircumcised groups, and conversely, 
4.6% and 5.2%, respectively, in rural areas—none of the 
differences being signiﬁ  cant [3]. In South Africa, the 
KwaZulu-Natal province, where few are circumcised, has a 
higher HIV seroprevalence than other provinces, reaching 
37% among antenatal clinic attendants in 2003. But, in the 
Eastern Cape, where circumcision is the rule, the dynamics 
of the epidemic are almost the same, simply lagging a 
few years behind, increasing from 4.5% in 1994 to 27% 
in 2003. Finally, it was argued that the large epidemic in 
Abidjan, Côte d’Ivoire, and surrounding areas in the late 
1980s was largely due to the lack of male circumcision of 
the local ethnic groups. This, however, did not impede the 
rapid increase in HIV infection among migrant workers 
from Burkina Faso and Mali living in Abidjan, who were 
circumcised.
For highly exposed men, such as men living in southern 
Africa, the choice is either using condoms consistently, 
with extremely low risk of becoming infected, or being 
circumcised, with relatively high risk of becoming infected. 
This is quite similar to women’s choice to either use a highly 
efﬁ  cacious contraceptive method or use a folk method. Some 
women make the second choice for religious reasons, with 
the obvious consequences. Is there a rationale for promoting 
the idea of circumcision when better choices are available? 
Regular condom use was found to be protective at the 
individual level and also effective for stopping HIV epidemics, 
as in Thailand [4,5].
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Concluding that “male circumcision should be regarded 
as an important public health intervention for preventing 
the spread of HIV” [1] appears overstated. Even though 
large-scale male circumcision could avert a number of HIV 
infections, theoretical calculations and empirical evidence 
show that it is unlikely to have a major public health impact, 
apart from the fact that achieving universal male circumcision 
is likely to be more difﬁ  cult than universal vaccination 
coverage or universal contraceptive use.  
Michel Garenne
Institut Pasteur
Paris, France
E-mail: mgarenne@pasteur.fr
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PfHRP2 Measures Schizogony, Not 
Mechanical Blockage
Ian Clark
As noted in Dondorp et al. [1], histidine-rich protein 2 
(PfHRP2) is released at schizont rupture as part of the 
regular 48-hour developmental cycle of the erythrocytic 
form of the parasite. Since this release of PfHRP2 into the 
circulation occurs while the parasitized red cell is adhering to 
vascular endothelium, it can act as an indirect marker for this 
sequestration. Therefore, as might be expected for a parasite 
that sequesters for a ﬁ  xed part of its repeated 48-hour cycle of 
development, both the total biomass and sequestered biomass 
were calculated to be associated with severity of disease.
The authors use these data to further the case for the 
traditional concept that disease symptoms in falciparum 
malaria—including coma, high lactate, and renal failure—
arise because erythrocytes containing mature forms of the 
parasites sequester within the microvasculature of the vital 
organs. We may safely infer from the authors’ previous 
publications their acceptance of the conventional wisdom 
that this sequestration mechanically obstructs vessels, leading 
to tissue hypoxia through poor oxygen transport.
Parasites are inside sequestering red cells when they 
burst and release PfHRP2, but it may be bursting, not 
sequestration, which matters most in disease pathogenesis. 
PfHRP2 is a marker for the degree of schizogony not, as 
implied, of vascular blockage caused by sequestration. Clinical 
tolerance to falciparum malaria, common in endemic areas 
in age groups with high parasite densities, demonstrates this 
well. Those who champion mechanical vascular obstruction 
must accept this as a state in which appreciable sequestration 
occurs only in harmless locations, such as larger veins and 
nonvital organs. It is not known where red cells containing 
mature parasites lodge in these individuals, and if they stop 
using these locations during serious illness. If they do not 
stop, PfHRP2 released from schizonts adhering in harmless 
locations would add to the total concentration in the 
circulation, but would not be a marker for obstruction.
Other molecules released at schizogony include the 
trigger(s) that generate the inﬂ  ammatory cytokines, which 
have formed the basis of a mainstream argument for the 
pathophysiology of malarial disease for the past 25 years 
(see [2,3,4] for recent reviews). An undiscussed reason 
for PfHRP2 release correlating with serious illness might 
be its value as a surrogate for these cytokine-triggering 
molecules liberated from bursting red cells postschizogony. 
An awareness of these concepts has allowed molecules of 
host origin, such as increased plasma levels of the soluble 
form of one of the receptors for tumor necrosis factor, to be 
considered alongside PfHRP2 as a marker for the parasite 
biomass [5].
If the cultural gap between the mechanical and the 
cytokine approach to malarial disease could be spanned, 
useful knowledge on roles of inﬂ  ammatory cytokines in 
sepsis, such as details of how cytokine-induced mitochondrial 
dysfunction causes a functional hypoxia [6,7], could more 
readily be applied to understanding malarial disease.  
Ian Clark 
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Canberra, Australian Capital Territory, Australia
E-mail: ian.clark@anu.edu.au 
References
1.  Dondorp AM, Desakorn V, Pongtavornpinyo W, Sahassananda D, Silamut 
K, et al. (2005) Estimation of the total parasite biomass in acute falciparum 
malaria from plasma PfHRP2. PLoS Med 2: e204. DOI: 10.1371/journal.
pmed.0020204
2.  Clark IA, Cowden WB (2003) The pathophysiology of falciparum malaria. 
Pharmacol Ther 99: 221–260.
3.  Maitland K, Marsh K (2004) Pathophysiology of severe malaria in children. 
Acta Trop 90: 131–140.
4.  Boutlis CS, Riley EM, Anstey NM, de Souza JB (2005) GPI in malaria 
pathogenesis and immunity: Potential for therapeutic inhibition and 
vaccination. Curr Topics Microbiol Immunol 197: 145–185.
5.  Ochola LB, Marsh K, Lowe B, Gal S, Pluschke G, Smith T (2005) Estimation 
of the sequestered parasite load in severe malaria patients using both host 
and parasite markers. Parasitology 131: 449–458.
6.  Singer M, De Santis V, Vitale D, Jeffcoate W (2004) Multiorgan failure is 
an adaptive, endocrine-mediated, metabolic response to overwhelming 
systemic inﬂ  ammation. Lancet 364: 545–548.
7.  Callahan LA, Supinski GS (2005) Sepsis induces diaphragm electron 
transport chain dysfunction and protein depletion. Am J Resp Crit Care 
Med 172: 861–868.
Citation: Clark I (2006) PfHRP2 measures schizogony, not mechanical blockage. 
PLoS Med 3(1): e68.
Copyright: © 2006 Ian Clark. This is an open-access article distributed under the 
terms of the Creative Commons Attribution License, which permits unrestricted use, 
distribution, and reproduction in any medium, provided the original author and 
source are credited.
Competing Interests: The author has declared that no competing interests exist.
DOI: 10.1371/journal.pmed.0030068
January 2006  |  Volume 3  |  Issue 1  |  e78  |  e68PLoS Medicine  |  www.plosmedicine.org 0145
Authors’ Reply: Response to Ian Clark
We are grateful for Ian Clark’s suggestions [1] in response 
to our research article [2]. Much remains to be learned 
about the pathogenesis of cerebral malaria. It is certainly 
hard to disprove that triggering local immune responses 
contributes in some way to the pathophysiology of cerebral 
malaria.  Local overproduction of NO, HMGB1, cytokines, 
or other mediators yet to be discovered could impair 
neurotransmission. But their roles remain hypothetical, 
and thus far, none of the proposed hypotheses have passed 
the stage of showing a correlation between the severity 
of disease and the proposed mediator. A role in murine 
malaria pathogenesis cannot be translated directly to 
human pathophysiology since the basic pathophysiological 
phenomena are essentially different in these animals. 
Although the concept of impairment of microcirculation in 
severe malaria by sequestered parasitized erythrocytes causing 
local tissue dysoxia, acidosis, and metabolic dysfunction 
is a simple one, there is considerable evidence that it is 
correct.  Lactate/pyruvate ratios are, in contrast with sepsis, 
clearly increased in severe malaria, which is compatible with 
anaerobic glycolysis as a source of lactate production [3]. Of 
the human malarias, only Plasmodium falciparum sequesters 
in vital organs, and this is also the species responsible for 
the vast majority of malaria-related deaths. Autopsy studies 
of fatal malaria cases show convincing correlations between 
extent of sequestration in the brain and coma as a presenting 
symptom [4]. Direct visualisation of the microcirculation in 
patients with severe malaria shows blockage of capillaries, 
which become patent after the patient’s recovery. Strong 
support for the central role of parasite sequestration in the 
pathophysiology of lethal malaria comes from the largest 
trial ever conducted on severe malaria, which showed 
that artesunate reduces mortality by 34% compared with 
quinine [5]. Both artesunate and quinine are very active 
against sequestered parasites, preventing their development 
to schizonts, but unlike quinine, artesunate is also active 
against the younger forms of the parasite, preventing their 
maturation and sequestration in the microcirculation of vital 
organs. The greatest mortality beneﬁ  t in this trial compared 
with quinine was in patients with high parasitaemias, 
indicating that prevention of sequestration (rather than 
prevention of schizont rupture) saved lives.  
Arjen Dondorp (AMDondorp@yahoo.com)
Nick White
Nick Day
Mahidol University
Bangkok, Thailand
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